Valneva SE, a specialty vaccine company, announced it will report its first quarter 2026 consolidated financial results on May 13, 2026. The company will host a live webcast at 3 p.m. CET/9 a.m. ET to discuss the results and provide a business update, accessible on its website. Valneva focuses on developing vaccines for infectious diseases, including a Lyme disease vaccine candidate partnered with Pfizer. This update is important for investors tracking the company's progress and vaccine pipeline development.
3M reported strong Q2 2026 results with EPS of $2.40 beating estimates of $2.27 and revenue of $6.5 billion surpassing expectations. The 2.4% revenue growth was driven by a 5.4% rise in organic sales and strategic pricing. The company raised its full...
Annaly Capital Management, a mortgage REIT, is expected to report Q2 earnings with a 2.7% increase in EPS to $0.75 and revenue of $639.8 million, driven by an 86.3% surge in net interest income. Despite a high 13% dividend yield, the company faces ri...
The Q2 2026 Global Economic Conditions Survey by ACCA and IMA reveals a sharp rise in operating costs for accountants and CFOs worldwide, driven by the Middle East conflict, soaring commodity prices, and supply chain issues. Over 75% of accountants a...
Argus Research increased its price target for Palo Alto Networks from $320 to $425, signaling a 25.66% potential upside. This boost reflects strong demand for cybersecurity services amid rising AI-related cyberattack concerns. The global cybersecurit...
HSBC upgraded Five Below stock to a Hold rating, indicating expected market-level performance. The company also earned a Strong Buy rating from Zacks, supported by a 10.4% rise in earnings estimates for the current year. Analysts project a mean price...
